Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chugai Pharmaceutical
Age
20–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Either MRA or placebo was administered at least 3 times in the preceding study, and there were confirmed to be no problems with respect to safety.
In the case of Patients whose participation in the current study was judged to be inappropriate because of problems in the preceding study with respect to safety, these Patients must have been in the methotrexate dose group in the preceding study.
You may not be if
Administered drugs such as infliximab, etanercept, and leflunomide within 12 weeks before administration of the study drug
Evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration of the study drug
Have not been registered by 3 months after the full code-breaking of the preceding study
Were administered plasma exchange therapy between initiation of the preceding study and the initial administration in the current study
Treated surgically (except for local surgery) within 4 weeks before administration of the study drug
